Patents by Inventor Tanja Badovinac-Crnjevic

Tanja Badovinac-Crnjevic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Subcutaneous HER2 antibody formulations
    Patent number: 11654105
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: May 23, 2023
    Assignees: Genentech, Inc., Hoffmann-La Roche
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
    Publication number: 20230092354
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Application
    Filed: August 22, 2022
    Publication date: March 23, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • PERTUZUMAB PLUS TRASTUZUMAB FIXED DOSE COMBINATION
    Publication number: 20210403599
    Abstract: The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.
    Type: Application
    Filed: June 28, 2021
    Publication date: December 30, 2021
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Tanja Badovinac-Crnjevic, Yu Chien Fredriksson, Sarah Heeson, Ihsan Hamdi Nijem, Whitney Paige Kirschbrown, Eleonora Restuccia
  • SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
    Publication number: 20210085597
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 25, 2021
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • Subcutaneous HER2 antibody formulations
    Patent number: 10849849
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: December 1, 2020
    Assignees: GENENTECH INC., HOFFMANN-LA ROCHE INC
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
    Publication number: 20180296470
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Application
    Filed: January 16, 2018
    Publication date: October 18, 2018
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth